Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies

Biochimica et Biophysica Acta - General Subjects

Volumn 1860, Issue 8, 2016, Pages 1655-1668

  Le, Ngoc Phuong Lan ^a   Bowden, Thomas A ^b   Struwe, Weston B ^a   Crispin, Max ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody; Effector function; Glycan; Glycosylation; Structure; Therapeutic antibodies

Indexed keywords

1 DEOXYNOJIRIMYCIN; ANTIBODY; CASTANOSPERMINE; CD209 ANTIGEN; FC RECEPTOR; GLYCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; KIFUNENSINE; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; POLYSACCHARIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CELL KILLING; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DEGLYCOSYLATION; DRUG MEGADOSE; FUCOSYLATION; GLYCOSYLATION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MAMMAL CELL; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T CELL LEUKEMIA; GENETICS; METABOLISM; PROCEDURES; PROTEIN ENGINEERING;

GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; POLYSACCHARIDES; PROTEIN ENGINEERING;

EID: 84973659190     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2016.04.016     Document Type: Article

References (285)

1. J.N. Arnold, M.R. Wormald, R.B. Sim, P.M. Rudd, and R.A. Dwek The impact of glycosylation on the biological function and structure of human immunoglobulins Annu. Rev. Immunol. 25 2007 21 50
2. O.H. Brekke, and I. Sandlie Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat. Rev. Drug Discov. 2 2003 52 62
3. R. Jefferis Glycosylation as a strategy to improve antibody-based therapeutics Nat. Rev. Drug Discov. 8 2009 226 234
4. M. Dalziel, M. Crispin, C.N. Scanlan, N. Zitzmann, and R.A. Dwek Emerging principles for the therapeutic exploitation of glycosylation Science 343 2014 1235681
5. R.L. Shields, J. Lai, R. Keck, L.Y. O'Connell, K. Hong, Y.G. Meng, S.H.A. Weikert, and L.G. Presta Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733 26740
6. T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, N. Hanai, and K. Shitara The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466 3473
7. A. Okazaki, E. Shoji-Hosaka, K. Nakamura, M. Wakitani, K. Uchida, S. Kakita, K. Tsumoto, I. Kumagai, and K. Shitara Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa J. Mol. Biol. 336 2004 1239 1249
8. S. Iida, H. Misaka, M. Inoue, M. Shibata, R. Nakano, N. Yamane-Ohnuki, M. Wakitani, K. Yano, K. Shitara, and M. Satoh Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa Clin. Cancer Res. 12 2006 2879 2887
9. R.M. Anthony, F. Nimmerjahn, D.J. Ashline, V.N. Reinhold, J.C. Paulson, and J.V. Ravetch Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 320 2008 373 376
10. Y. Kaneko, F. Nimmerjahn, and J.V. Ravetch Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 2006 670 673
11. N. Washburn, I. Schwab, D. Ortiz, N. Bhatnagar, J.C. Lansing, A. Medeiros, S. Tyler, D. Mekala, E. Cochran, H. Sarvaiya, K. Garofalo, R. Meccariello, J.W. Meador, L. Rutitzky, B.C. Schultes, L. Ling, W. Avery, F. Nimmerjahn, A.M. Manning, G.V. Kaundinya, and C.J. Bosques Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity Proc. Natl. Acad. Sci. 112 2015 E1297 E1306
12. I. Schwab, S. Mihai, M. Seeling, M. Kasperkiewicz, R.J. Ludwig, and F. Nimmerjahn Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo Eur. J. Immunol. 44 2014 1444 1453
13. D.R. Davies, and H. Metzger Structural basis of antibody function Annu. Rev. Immunol. 1 1983 87 117
14. E.A. Padlan Anatomy of the antibody molecule Mol. Immunol. 31 1994 169 217
15. F. Nimmerjahn, and J.V. Ravetch Antibody-mediated modulation of immune responses Immunol. Rev. 236 2010 265 275
16. P.H. Schur IgG subclasses: a historical perspective Monogr. Allergy 23 1988 1 11
17. C.I. Bindon, G. Hale, M. Brüggemann, and H. Waldmann Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q J. Exp. Med. 168 1988 127 142
18. V.N. Schumaker, M.A. Calcott, H.L. Spiegelberg, and H.J. Muller-Eberhard Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement Biochemistry 15 1976 5175 5181
19. M.H. Tao, R.I. Smith, and S.L. Morrison Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation J. Exp. Med. 178 1993 661 667
20. P. Bruhns, B. Iannascoli, P. England, D.A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses Blood 113 2009 3716 3725
21. D.R. Burton, L. Gregory, and R. Jefferis Aspects of the molecular structure of IgG subclasses Monogr. Allergy 19 1986 7 35
22. K.H. Roux, L. Strelets, and T.E. Michaelsen Flexibility of human IgG subclasses J. Immunol. 159 1997 3372 3382
23. J. Deisenhofer Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution Biochemistry 20 1981 2361 2370
24. S. Foss, R. Watkinson, I. Sandlie, L.C. James, and J.T. Andersen TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity Immunol. Rev. 268 2015 328 339
25. R.L. Shields, A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, J.A. Fox, and L.G. Presta High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR J. Biol. Chem. 276 2001 6591 6604
26. A.R. Duncan, and G. Winter The binding site for C1q on IgG Nature 332 1988 738 740
27. W.L. DeLano, M.H. Ultsch, A.M. de Vos, and J.A. Wells Convergent solutions to binding at a protein-protein interface Science 287 2000 1279 1283
28. R. Kornfeld, and S. Kornfeld Assembly of asparagine-linked oligosaccharides Annu. Rev. Biochem. 54 1985 631 664
29. G. Lauc, J.E. Huffman, M. Pucic, L. Zgaga, B. Adamczyk, A. Muzinic, M. Novokmet, O. Polasek, O. Gornik, J. Kristic, T. Keser, V. Vitart, B. Scheijen, H.W. Uh, M. Molokhia, A.L. Patrick, P. McKeigue, I. Kolcic, I.K. Lukic, O. Swann, F.N. van Leeuwen, L.R. Ruhaak, J.J. Houwing-Duistermaat, P.E. Slagboom, M. Beekman, A.J. de Craen, A.M. Deelder, Q. Zeng, W. Wang, N.D. Hastie, U. Gyllensten, J.F. Wilson, M. Wuhrer, A.F. Wright, P.M. Rudd, C. Hayward, Y. Aulchenko, H. Campbell, and I. Rudan Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers PLoS Genet. 9 2013 e1003225
30. K. Masuda, Y. Yamaguchi, K. Kato, N. Takahashi, I. Shimada, and Y. Arata Pairing of oligosaccharides in the Fc region of immunoglobulin G FEBS Lett. 473 2000 349 357
31. T.B. Parsons, W.B. Struwe, J. Gault, K. Yamamoto, T.A. Taylor, R. Raj, K. Wals, S. Mohammed, C.V. Robinson, J.L. Benesch, and B.G. Davis Optimal synthetic glycosylation of a therapeutic antibody Angew. Chem. 55 2016 2361 2367
32. T.S. Raju, J.B. Briggs, S.M. Chamow, M.E. Winkler, and A.J.S. Jones Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues Biochemistry 40 2001 8868 8876
33. G. Zauner, M.H.J. Selman, A. Bondt, Y. Rombouts, D. Blank, A.M. Deelder, and M. Wuhrer Glycoproteomic analysis of antibodies Mol. Cell. Proteomics 12 2013 856 865
34. R. Jefferis Glycosylation of recombinant antibody therapeutics Biotechnol. Prog. 21 2005 11 16
35. D.J. Harvey, M. Crispin, C. Scanlan, B.B. Singer, L. Lucka, V.T. Chang, C.M. Radcliffe, S. Thobhani, C.T. Yuen, and P.M. Rudd Differentiation between isomeric triantennary N-linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting (beta1-4-GlcNAc) residue in N-glycans from IgG Rapid Commun. Mass Spectrom. 22 2008 1047 1052
36. J. Stadlmann, A. Weber, M. Pabst, H. Anderle, R. Kunert, H.J. Ehrlich, H. Peter Schwarz, and F. Altmann A close look at human IgG sialylation and subclass distribution after lectin fractionation Proteomics 9 2009 4143 4153
37. M. Wuhrer, J.C. Stam, F.E. van de Geijn, C.A.M. Koeleman, C.T. Verrips, R.J.E.M. Dolhain, C.H. Hokke, and A.M. Deelder Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum Proteomics 7 2007 4070 4081
38. A. Youings, S.C. Chang, R.A. Dwek, and I.G. Scragg Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients Biochem. J. 314 1996 621 630
39. M.R. Wormald, P.M. Rudd, D.J. Harvey, S.-C. Chang, I.G. Scragg, and R.A. Dwek Variations in oligosaccharide - protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides Biochemistry 36 1997 1370 1380
40. D. Dunn-Walters, L. Boursier, and J. Spencer Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions Mol. Immunol. 37 2000 107 113
41. M. Holland, H. Yagi, N. Takahashi, K. Kato, C.O.S. Savage, D.M. Goodall, and R. Jefferis Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis Biochim. Biophys. Acta 1760 2006 669 677
42. R. Jefferis Antibody therapeutics: isotype and glycoform selection Expert. Opin. Biol. Ther. 7 2007 1401 1413
43. Q.M. Hanson, and A.W. Barb A perspective on the structure and receptor binding properties of immunoglobulin G Fc Biochemistry 54 2015 2931 2942
44. T.A. Bowden, K. Baruah, C.H. Coles, D.J. Harvey, X. Yu, B.D. Song, D.I. Stuart, A.R. Aricescu, C.N. Scanlan, E.Y. Jones, and M. Crispin Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis J. Am. Chem. Soc. 134 2012 17554 17563
45. M. Crispin, X. Yu, and T.A. Bowden Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy Proc. Natl. Acad. Sci. U. S. A. 110 2013 E3544 E3546
46. S. Krapp, Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity J. Mol. Biol. 325 2003 979 989
47. S. Matsumiya, Y. Yamaguchi, J. Saito, M. Nagano, H. Sasakawa, S. Otaki, M. Satoh, K. Shitara, and K. Kato Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1 J. Mol. Biol. 368 2007 767 779
48. D.J. Harvey, M. Crispin, B.E. Moffatt, S.L. Smith, R.B. Sim, P.M. Rudd, and R.A. Dwek Identification of high-mannose and multiantennary complex-type N-linked glycans containing alpha-galactose epitopes from nurse shark IgM heavy chain Glycoconj. J. 26 2009 1055 1064
49. E.E. Idusogie, L.G. Presta, H. Gazzano-Santoro, K. Totpal, P.Y. Wong, M. Ultsch, Y.G. Meng, and M.G. Mulkerrin Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc J. Immunol. 164 2000 4178 4184
50. A.W. Barb, and J.H. Prestegard NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic Nat. Chem. Biol. 7 2011 147 153
51. X. Yu, K. Baruah, D.J. Harvey, S. Vasiljevic, D.S. Alonzi, B.D. Song, M.K. Higgins, T.A. Bowden, C.N. Scanlan, and M. Crispin Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies J. Am. Chem. Soc. 135 2013 9723 9732
52. P. Sondermann, A. Pincetic, J. Maamary, K. Lammens, and J.V. Ravetch Reply to Crispin et al.: molecular model that accounts for the biological and physical properties of sialylated fc Proc. Natl. Acad. Sci. U. S. A. 110 2013 E3547
53. P. Sondermann, A. Pincetic, J. Maamary, K. Lammens, and J.V. Ravetch General mechanism for modulating immunoglobulin effector function Proc. Natl. Acad. Sci. U. S. A. 110 2013 9868 9872
54. A.W. Barb, L. Meng, Z. Gao, R.W. Johnson, K.W. Moremen, and J.H. Prestegard NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation Biochemistry 51 2012 4618 4626
55. A.A. Ahmed, J. Giddens, A. Pincetic, J.V. Lomino, J.V. Ravetch, L.X. Wang, and P.J. Bjorkman Structural characterization of anti-inflammatory immunoglobulin G Fc proteins J. Mol. Biol. 426 2014 3166 3179
56. J. Fang, J. Richardson, Z. Du, and Z. Zhang Effect of Fc-glycan structure on the conformational stability of IgG revealed by hydrogen/deuterium exchange and limited proteolysis Biochemistry 55 2016 860 868
57. J.R. Rich, and S.G. Withers Emerging methods for the production of homogeneous human glycoproteins Nat. Chem. Biol. 5 2009 206 215
58. L.-X. Wang, and J.V. Lomino Emerging technologies for making glycan-defined glycoproteins ACS Chem. Biol. 7 2012 110 122
59. M. Satoh, S. Iida, and K. Shitara Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies Expert. Opin. Biol. Ther. 6 2006 1161 1173
60. K. Mori, S. Iida, N. Yamane-Ohnuki, Y. Kanda, R. Kuni-Kamochi, R. Nakano, H. Imai-Nishiya, A. Okazaki, T. Shinkawa, A. Natsume, R. Niwa, K. Shitara, and M. Satoh Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies Cytotechnology 55 2007 109 114
61. Y. Kanda, N. Yamane-Ohnuki, N. Sakai, K. Yamano, R. Nakano, M. Inoue, H. Misaka, S. Iida, M. Wakitani, Y. Konno, K. Yano, K. Shitara, S. Hosoi, and M. Satoh Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC Biotechnol. Bioeng. 94 2006 680 688
62. E. Miyoshi, K. Noda, Y. Yamaguchi, S. Inoue, Y. Ikeda, W. Wang, J.H. Ko, N. Uozumi, W. Li, and N. Taniguchi The α1-6-fucosyltransferase gene and its biological significance Biochim. Biophys. Acta Gen. Subj. 1473 1999 9 20
63. K. Mori, R. Kuni-Kamochi, N. Yamane-Ohnuki, M. Wakitani, K. Yamano, H. Imai, Y. Kanda, R. Niwa, S. Iida, K. Uchida, K. Shitara, and M. Satoh Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA Biotechnol. Bioeng. 88 2004 901 908
64. N. Yamane-Ohnuki, S. Kinoshita, M. Inoue-Urakubo, M. Kusunoki, S. Iida, R. Nakano, M. Wakitani, R. Niwa, M. Sakurada, K. Uchida, K. Shitara, and M. Satoh Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity Biotechnol. Bioeng. 87 2004 614 622
65. A. Beck, and J.M. Reichert Marketing approval of mogamulizumab: a triumph for glyco-engineering mAbs 4 2012 419 425
66. D.J. Becker, and J.B. Lowe Fucose: biosynthesis and biological function in mammals Glycobiology 13 2003 41R 53R
67. Y. Kanda, H. Imai-Nishiya, R. Kuni-Kamochi, K. Mori, M. Inoue, K. Kitajima-Miyama, A. Okazaki, S. Iida, K. Shitara, and M. Satoh Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics J. Biotechnol. 130 2007 300 310
68. H. Imai-Nishiya, K. Mori, M. Inoue, M. Wakitani, S. Iida, K. Shitara, and M. Satoh Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC BMC Biotechnol. 7 2007 84
69. P. Umana, J. Jean-Mairet, R. Moudry, H. Amstutz, and J.E. Bailey Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nat. Biotechnol. 17 1999 176 180
70. M. Schuster, P. Umana, C. Ferrara, P. Brünker, C. Gerdes, G. Waxenecker, S. Wiederkum, C. Schwager, H. Loibner, G. Himmler, and G.C. Mudde Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering Cancer Res. 65 2005 7934 7941
71. C. Ferrara, P. Brünker, T. Suter, S. Moser, U. Püntener, and P. Umaña Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II Biotechnol. Bioeng. 93 2006 851 861
72. J. Davies, L. Jiang, L.Z. Pan, M.J. LaBarre, D. Anderson, and M. Reff Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII Biotechnol. Bioeng. 74 2001 288 294
73. A.L. Gagez, and G. Cartron Obinutuzumab: a new class of anti-CD20 monoclonal antibody Curr. Opin. Oncol. 26 2014 484 491
74. R. Jassal, N. Jenkins, J. Charlwood, P. Camilleri, R. Jefferis, and J. Lund Sialylation of human IgG-Fc carbohydrate by transfected rat α2,6-sialyltransferase Biochem. Biophys. Res. Commun. 286 2001 243 249
75. M. Onitsuka, W.-D. Kim, H. Ozaki, A. Kawaguchi, K. Honda, H. Kajiura, K. Fujiyama, R. Asano, I. Kumagai, H. Ohtake, and T. Omasa Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells Appl. Microbiol. Biotechnol. 94 2012 69 80
76. L. Meuris, F. Santens, G. Elson, N. Festjens, M. Boone, A. Dos Santos, S. Devos, F. Rousseau, E. Plets, E. Houthuys, P. Malinge, G. Magistrelli, L. Cons, L. Chatel, B. Devreese, and N. Callewaert GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins Nat. Biotechnol. 32 2014 485 489
77. P.J. Reeves, N. Callewaert, R. Contreras, and H.G. Khorana Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line Proc. Natl. Acad. Sci. 99 2002 13419 13424
78. L.D. Powell Inhibition of N-linked glycosylation, in: current protocols in immunology 2001 John Wiley & Sons Inc.
79. T.R. Gemmill, and R.B. Trimble Overview of N- and O-linked oligosaccharide structures found in various yeast species Biochim. Biophys. Acta Gen. Subj. 1426 1999 227 237
80. M.J. Betenbaugh, N. Tomiya, and S. Narang 4.32 - glycoengineering: recombinant glycoproteins H. Kamerling, Comprehensive Glycoscience 2007 Elsevier Oxford 607 642
81. Y. Chiba, and Y. Jigami Production of humanized glycoproteins in bacteria and yeasts Curr. Opin. Chem. Biol. 11 2007 670 676
82. B.-K. Choi, P. Bobrowicz, R.C. Davidson, S.R. Hamilton, D.H. Kung, H. Li, R.G. Miele, J.H. Nett, S. Wildt, and T.U. Gerngross Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris Proc. Natl. Acad. Sci. 100 2003 5022 5027
83. R.C. Davidson, J.H. Nett, E. Renfer, H. Li, T.A. Stadheim, B.J. Miller, R.G. Miele, S.R. Hamilton, B.-K. Choi, T.I. Mitchell, and S. Wildt Functional analysis of the ALG3 gene encoding the Dol-P-Man: Man5GlcNAc2-PP-Dol mannosyltransferase enzyme of P. pastoris Glycobiology 14 2004 399 407
84. W. Vervecken, V. Kaigorodov, N. Callewaert, S. Geysens, K. De Vusser, and R. Contreras In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris Appl. Environ. Microbiol. 70 2004 2639 2646
85. S.R. Hamilton, P. Bobrowicz, B. Bobrowicz, R.C. Davidson, H. Li, T. Mitchell, J.H. Nett, S. Rausch, T.A. Stadheim, H. Wischnewski, S. Wildt, and T.U. Gerngross Production of complex human glycoproteins in yeast Science 301 2003 1244 1246
86. S.R. Hamilton, R.C. Davidson, N. Sethuraman, J.H. Nett, Y. Jiang, S. Rios, P. Bobrowicz, T.A. Stadheim, H. Li, B.-K. Choi, D. Hopkins, H. Wischnewski, J. Roser, T. Mitchell, R.R. Strawbridge, J. Hoopes, S. Wildt, and T.U. Gerngross Humanization of yeast to produce complex terminally sialylated glycoproteins Science 313 2006 1441 1443
87. P. Bobrowicz, R.C. Davidson, H. Li, T.I. Potgieter, J.H. Nett, S.R. Hamilton, T.A. Stadheim, R.G. Miele, B. Bobrowicz, T. Mitchell, S. Rausch, E. Renfer, and S. Wildt Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose Glycobiology 14 2004 757 766
88. H. Li, N. Sethuraman, T.A. Stadheim, D. Zha, B. Prinz, N. Ballew, P. Bobrowicz, B.-K. Choi, W.J. Cook, M. Cukan, N.R. Houston-Cummings, R. Davidson, B. Gong, S.R. Hamilton, J.P. Hoopes, Y. Jiang, N. Kim, R. Mansfield, J.H. Nett, S. Rios, R. Strawbridge, S. Wildt, and T.U. Gerngross Optimization of humanized IgGs in glycoengineered Pichia pastoris Nat. Biotechnol. 24 2006 210 215
89. P.P. Jacobs, S. Geysens, W. Vervecken, R. Contreras, and N. Callewaert Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology Nat. Protoc. 4 2008 58 70
90. K.M. Cox, J.D. Sterling, J.T. Regan, J.R. Gasdaska, K.K. Frantz, C.G. Peele, A. Black, D. Passmore, C. Moldovan-Loomis, M. Srinivasan, S. Cuison, P.M. Cardarelli, and L.F. Dickey Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor Nat. Biotechnol. 24 2006 1591 1597
91. R. Strasser, J. Stadlmann, M. Schähs, G. Stiegler, H. Quendler, L. Mach, J. Glössl, K. Weterings, M. Pabst, and H. Steinkellner Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure Plant Biotechnol. J. 6 2008 392 402
92. A. Castilho, P. Gattinger, J. Grass, J. Jez, M. Pabst, F. Altmann, M. Gorfer, R. Strasser, and H. Steinkellner N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans Glycobiology 21 2011 813 823
93. A. Castilho, R. Strasser, J. Stadlmann, J. Grass, J. Jez, P. Gattinger, R. Kunert, H. Quendler, M. Pabst, R. Leonard, F. Altmann, and H. Steinkellner In planta protein sialylation through overexpression of the respective mammalian pathway J. Biol. Chem. 285 2010 15923 15930
94. A. Loos, C. Gruber, F. Altmann, U. Mehofer, F. Hensel, M. Grandits, C. Oostenbrink, G. Stadlmayr, P.G. Furtmüller, and H. Steinkellner Expression and glycoengineering of functionally active heteromultimeric IgM in plants Proc. Natl. Acad. Sci. 111 2014 6263 6268
95. J.J. Goodfellow, K. Baruah, K. Yamamoto, C. Bonomelli, B. Krishna, D.J. Harvey, M. Crispin, C.N. Scanlan, and B.G. Davis An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling J. Am. Chem. Soc. 134 2012 8030 8033
96. L.-X. Wang Chemoenzymatic synthesis of glycopeptides and glycoproteins through endoglycosidase-catalyzed transglycosylation Carbohydr. Res. 343 2008 1509 1522
97. B. Li, Y. Zeng, S. Hauser, H. Song, and L.-X. Wang Highly efficient endoglycosidase-catalyzed synthesis of glycopeptides using oligosaccharide oxazolines as donor substrates J. Am. Chem. Soc. 127 2005 9692 9693
98. B. Li, H. Song, S. Hauser, and L.-X. Wang A highly efficient chemoenzymatic approach toward glycoprotein synthesis Org. Lett. 8 2006 3081 3084
99. T.W.D.F. Rising, T.D.W. Claridge, N. Davies, D.P. Gamblin, J.W.B. Moir, and A.J. Fairbanks Synthesis of N-glycan oxazolines: donors for endohexosaminidase catalysed glycosylation Carbohydr. Res. 341 2006 1574 1596
100. W. Huang, J. Giddens, S.-Q. Fan, C. Toonstra, and L.-X. Wang Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions J. Am. Chem. Soc. 134 2012 12308 12318
101. M. Umekawa, W. Huang, B. Li, K. Fujita, H. Ashida, L.-X. Wang, and K. Yamamoto Mutants of mucor hiemalis endo-β-N-acetylglucosaminidase show enhanced transglycosylation and glycosynthase-like activities J. Biol. Chem. 283 2008 4469 4479
102. W. Huang, C. Li, B. Li, M. Umekawa, K. Yamamoto, X. Zhang, and L.-X. Wang Glycosynthases enable a highly efficient chemoenzymatic synthesis of N-glycoproteins carrying intact natural N-glycans J. Am. Chem. Soc. 131 2009 2214 2223
103. C.D. Heidecke, Z. Ling, N.C. Bruce, J.W.B. Moir, T.B. Parsons, and A.J. Fairbanks Enhanced glycosylation with mutants of endohexosaminidase A (Endo A) Chembiochem 9 2008 2045 2051
104. Y. Wei, C. Li, W. Huang, B. Li, S. Strome, and L.-X. Wang Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation Biochemistry 47 2008 10294 10304
105. G. Zou, H. Ochiai, W. Huang, Q. Yang, C. Li, and L.-X. Wang Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor J. Am. Chem. Soc. 133 2011 18975 18991
106. C.-W. Lin, M.-H. Tsai, S.-T. Li, T.-I. Tsai, K.-C. Chu, Y.-C. Liu, M.-Y. Lai, C.-Y. Wu, Y.-C. Tseng, S.S. Shivatare, C.-H. Wang, P. Chao, S.-Y. Wang, H.-W. Shih, Y.-F. Zeng, T.-H. You, J.-Y. Liao, Y.-C. Tu, Y.-S. Lin, H.-Y. Chuang, C.-L. Chen, C.-S. Tsai, C.-C. Huang, N.-H. Lin, C. Ma, C.-Y. Wu, and C.-H. Wong A common glycan structure on immunoglobulin G for enhancement of effector functions Proc. Natl. Acad. Sci. 112 2015 10611 10616
107. J. Giddens, and L.-X. Wang Chemoenzymatic glyco-engineering of monoclonal antibodies A. Castilho, Glyco-Engineering 1321 2015 Springer New York 375 387
108. R. Niwa, A. Natsume, A. Uehara, M. Wakitani, S. Iida, K. Uchida, M. Satoh, and K. Shitara IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides J. Immunol. Methods 306 2005 151 160
109. A. Natsume, M. Wakitani, N. Yamane-Ohnuki, E. Shoji-Hosaka, R. Niwa, K. Uchida, M. Satoh, and K. Shitara Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region J. Immunol. Methods 306 2005 93 103
110. R. Niwa, M. Sakurada, Y. Kobayashi, A. Uehara, K. Matsushima, R. Ueda, K. Nakamura, and K. Shitara Enhanced natural killer cell binding and activation by low-fucose igg1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density Clin. Cancer Res. 11 2005 2327 2336
111. K. Masuda, T. Kubota, E. Kaneko, S. Iida, M. Wakitani, Y. Kobayashi-Natsume, A. Kubota, K. Shitara, and K. Nakamura Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity Mol. Immunol. 44 2007 3122 3131
112. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Blood 99 2002 754 758
113. W.-K. Weng, and R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J. Clin. Oncol. 21 2003 3940 3947
114. S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res. 64 2004 4664 4669
115. S. de Haij, J.H.M. Jansen, P. Boross, F.J. Beurskens, J.E. Bakema, D.L. Bos, A. Martens, J.S. Verbeek, P.W.H.I. Parren, J.G.J. van de Winkel, and J.H.W. Leusen In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling Cancer Res. 70 2010 3209 3217
116. R. Niwa, E. Shoji-Hosaka, M. Sakurada, T. Shinkawa, K. Uchida, K. Nakamura, K. Matsushima, R. Ueda, N. Hanai, and K. Shitara Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma Cancer Res. 64 2004 2127 2133
117. L. Bologna, E. Gotti, M. Manganini, A. Rambaldi, T. Intermesoli, M. Introna, and J. Golay Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab J. Immunol. 186 2011 3762 3769
118. R. Herbst, Y. Wang, S. Gallagher, N. Mittereder, E. Kuta, M. Damschroder, R. Woods, D.C. Rowe, L. Cheng, K. Cook, K. Evans, G.P. Sims, D.S. Pfarr, M.A. Bowen, W. Dall'Acqua, M. Shlomchik, T.F. Tedder, P. Kiener, B. Jallal, H. Wu, and A.J. Coyle B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody J. Pharmacol. Exp. Ther. 335 2010 213 222
119. T. Ishida, T. Joh, N. Uike, K. Yamamoto, A. Utsunomiya, S. Yoshida, Y. Saburi, T. Miyamoto, S. Takemoto, H. Suzushima, K. Tsukasaki, K. Nosaka, H. Fujiwara, K. Ishitsuka, H. Inagaki, M. Ogura, S. Akinaga, M. Tomonaga, K. Tobinai, and R. Ueda Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study J. Clin. Oncol. 30 2012 837 842
120. T. Ishii, T. Ishida, A. Utsunomiya, A. Inagaki, H. Yano, H. Komatsu, S. Iida, K. Imada, T. Uchiyama, S. Akinaga, K. Shitara, and R. Ueda Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma Clin. Cancer Res. 16 2010 1520 1531
121. S. Matsumiya, Y. Yamaguchi, J.-i. Saito, M. Nagano, H. Sasakawa, S. Otaki, M. Satoh, K. Shitara, and K. Kato Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1 J. Mol. Biol. 368 2007 767 779
122. C. Ferrara, S. Grau, C. Jäger, P. Sondermann, P. Brünker, I. Waldhauer, M. Hennig, A. Ruf, A.C. Rufer, M. Stihle, P. Umaña, and J. Benz Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose Proc. Natl. Acad. Sci. 108 2011 12669 12674
123. T. Mizushima, H. Yagi, E. Takemoto, M. Shibata-Koyama, Y. Isoda, S. Iida, K. Masuda, M. Satoh, and K. Kato Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans Genes Cells 16 2011 1071 1080
124. A.L. Wallace, and M.W. Howell Fanger, Role of Fc gamma receptors in cancer and infectious disease Journal of Leukocyte Biology 55 1994 816 826
125. S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-ffect relationship Cancer Res. 64 2004 4664 4669
126. S. Zompi, and F. Colucci Anatomy of a murder - signal transduction pathways leading to activation of natural killer cells Immunol. Lett. 97 2005 31 39
127. C.M. Eischen, J.D. Schilling, D.H. Lynch, P.H. Krammer, and P.J. Leibson Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis J. Immunol. 156 1996 2693 2699
128. C. Koller, and A. LoBuglio Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burst Blood 58 1981 293 299
129. P. Boross, J.H.M. Jansen, A. Pastula, C.E. van der Poel, and J.H.W. Leusen Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice Immunol. Lett. 143 2012 44 52
130. F.N. Cho, T.H. Chang, C.W. Shu, M.C. Ko, S.K. Liao, K.H. Wu, M.S. Yu, S.J. Lin, Y.C. Hong, C.H. Chen, C.H. Hung, and Y.H. Chang Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis PLoS One 9 2014 e109352
131. S. Preithner, S. Elm, S. Lippold, M. Locher, A. Wolf, A.J.Dd. Silva, P.A. Baeuerle, and N.S. Prang High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G Mol. Immunol. 43 2006 1183 1193
132. Y. Vugmeyster, and K. Howell Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG Int. Immunopharmacol. 4 2004 1117 1124
133. S. Iida, R. Kuni-Kamochi, K. Mori, H. Misaka, M. Inoue, A. Okazaki, K. Shitara, and M. Satoh Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood BMC Cancer 9 2009 1 12
134. A. Nechansky, M. Schuster, W. Jost, P. Siegl, S. Wiederkum, G. Gorr, and R. Kircheis Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies Mol. Immunol. 44 2007 1815 1817
135. S. Preithner, S. Elm, S. Lippold, M. Locher, A. Wolf, A.J. da Silva, P.A. Baeuerle, and N.S. Prang High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G Mol. Immunol. 43 2006 1183 1193
136. J.G. Kelton, J. Singer, C. Rodger, J. Gauldie, P. Horsewood, and P. Dent The concentration of IgG in the serum is a major determinant of Fc-dependent reticuloendothelial function Blood 66 1985 490 495
137. R. Niwa, S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism Clin. Cancer Res. 10 2004 6248 6255
138. R. Niwa, and M. Satoh The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology J. Pharm. Sci. 104 2015 930 941
139. M. Shibata-Koyama, S. Iida, H. Misaka, K. Mori, K. Yano, K. Shitara, and M. Satoh Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils Exp. Hematol. 37 2009 309 321
140. D. Tudor, and M. Bomsel The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner AIDS (London, England) 25 2011 751 759
141. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
142. V. Minard-Colin, Y. Xiu, J.C. Poe, M. Horikawa, C.M. Magro, Y. Hamaguchi, K.M. Haas, and T.F. Tedder Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV Blood 112 2008 1205 1213
143. M. Peipp, J.J. Lammerts van Bueren, T. Schneider-Merck, W.W.K. Bleeker, M. Dechant, T. Beyer, R. Repp, P.H.C. van Berkel, T. Vink, J.G.J. van de Winkel, P.W.H.I. Parren, and T. Valerius Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells Blood 112 2008 2390 2399
144. P.-L. Lim, and M. Zouali Pathogenic autoantibodies: emerging insights into tissue injury Immunol. Lett. 103 2006 17 26
145. R.H. Scofield Autoantibodies as predictors of disease Lancet 363 2004 1544 1546
146. K.S. Nandakumar, E. Bajtner, L. Hill, B. Böhm, M.J. Rowley, H. Burkhardt, and R. Holmdahl Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation Arthritis Rheum. 58 2008 184 196
147. S.F. Amirahmadi, S. Whittingham, D.E. Crombie, K.S. Nandakumar, R. Holmdahl, I.R. Mackay, M.-P. van Damme, and M.J. Rowley Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells Arthritis Rheum. 52 2005 1897 1906
148. C. Sitaru, and D. Zillikens Mechanisms of blister induction by autoantibodies Exp. Dermatol. 14 2005 861 875
149. C. Sitaru, S. Mihai, and D. Zillikens The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases Arch. Dermatol. Res. 299 2007 1 8
150. R.B. Colvin, and R.N. Smith Antibody-mediated organ-allograft rejection Nat. Rev. Immunol. 5 2005 807 817
151. M. Allhorn, and M. Collin Sugar-free antibodies - the bacterial solution to autoimmunity? Ann. N. Y. Acad. Sci. 1173 2009 664 669
152. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
153. F. Bard, C. Cannon, R. Barbour, R.-L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid [beta]-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
154. J.-C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul Immunization reverses memory deficits without reducing brain A[beta] burden in Alzheimer's disease model Nat. Neurosci. 5 2002 452 457
155. L.A. Kotilinek, B. Bacskai, M. Westerman, T. Kawarabayashi, L. Younkin, B.T. Hyman, S. Younkin, and K.H. Ashe Reversible memory loss in a mouse transgenic model of Alzheimer's disease J. Neurosci. 22 2002 6331 6335
156. D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon, and D. Morgan Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J. Neurosci. 24 2004 6144 6151
157. M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Mathews, and M. Jucker Cerebral hemorrhage after passive anti-Aβ immunotherapy Science 298 2002 1379
158. M.M. Racke, L.I. Boone, D.L. Hepburn, M. Parsadainian, M.T. Bryan, D.K. Ness, K.S. Piroozi, W.H. Jordan, D.D. Brown, W.P. Hoffman, D.M. Holtzman, K.R. Bales, B.D. Gitter, P.C. May, S.M. Paul, and R.B. DeMattos Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β J. Neurosci. 25 2005 629 636
159. D.M. Wilcock, J. Alamed, P.E. Gottschall, J. Grimm, A. Rosenthal, J. Pons, V. Ronan, K. Symmonds, M.N. Gordon, and D. Morgan Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice J. Neurosci. 26 2006 5340 5346
160. K. Takata, C. Hirata-Fukae, A.G. Becker, S. Chishiro, A.J. Gray, K. Nishitomi, A.H. Franz, G. Sakaguchi, A. Kato, M.P. Mattson, F.M. LaFerla, P.S. Aisen, Y. Kitamura, and Y. Matsuoka Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration Eur. J. Neurosci. 26 2007 2458 2468
161. S. Rebe, and B. Solomon Deglycosylation of anti-ß amyloid antibodies inhibits microglia activation in BV-2 cellular model Am. J. Alzheimers Dis. Other Demen. 20 2005 303 313
162. N. Carty, D. Wilcock, A. Rosenthal, J. Grimm, J. Pons, V. Ronan, P. Gottschall, M. Gordon, and D. Morgan Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice J. Neuroinflammation 3 2006 11
163. L. Tradtrantip, J. Ratelade, H. Zhang, and A.S. Verkman Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody Ann. Neurol. 73 2013 77 85
164. T. Bakchoul, A. Greinacher, U.J. Sachs, A. Krautwurst, H. Renz, H. Harb, G. Bein, P.J. Newman, and S. Santoso Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia Blood 122 2013 321 327
165. H. Albert, M. Collin, D. Dudziak, J.V. Ravetch, and F. Nimmerjahn In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner Proc. Natl. Acad. Sci. 105 2008 15005 15009
166. M. Benkhoucha, N. Molnarfi, M.-L. Santiago-Raber, M. Weber, D. Merkler, M. Collin, and P. Lalive IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis J. Neuroinflammation 9 2012 209
167. M. Hirose, K. Vafia, K. Kalies, S. Groth, J. Westermann, D. Zillikens, R.J. Ludwig, M. Collin, and E. Schmidt Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen J. Autoimmun. 39 2012 304 314
168. C. Lood, M. Allhorn, R. Lood, B. Gullstrand, A.I. Olin, L. Rönnblom, L. Truedsson, M. Collin, and A.A. Bengtsson IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? Arthritis Rheum. 64 2012 2698 2706
169. K.S. Nandakumar, M. Collin, A. Olsén, F. Nimmerjahn, A.M. Blom, J.V. Ravetch, and R. Holmdahl Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis Eur. J. Immunol. 37 2007 2973 2982
170. M. Collin, and A. Olsén Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes Infect. Immun. 71 2003 2983 2992
171. K. Baruah, T.A. Bowden, B.A. Krishna, R.A. Dwek, M. Crispin, and C.N. Scanlan Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions J. Mol. Biol. 420 2012 1 7
172. J. Garbe, and M. Collin Bacterial hydrolysis of host glycoproteins - powerful protein modification and efficient nutrient acquisition J. Innate Immun. 4 2012 121 131
173. M. Collin, M.D. Svensson, A.G. Sjöholm, J.C. Jensenius, U. Sjöbring, and A. Olsén EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis Infect. Immun. 70 2002 6646 6651
174. J. Sjögren, C.Y. Okumura, M. Collin, V. Nizet, and A. Hollands Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence BMC Microbiol. 11 2011 1 7
175. M. Collin, O. Shannon, and L. Björck IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions Proc. Natl. Acad. Sci. 105 2008 4265 4270
176. B. Trastoy, J.V. Lomino, B.G. Pierce, L.G. Carter, S. Günther, J.P. Giddens, G.A. Snyder, T.M. Weiss, Z. Weng, L.-X. Wang, and E.J. Sundberg Crystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodies Proc. Natl. Acad. Sci. 111 2014 6714 6719
177. E.V. Dixon, J.K. Claridge, D.J. Harvey, K. Baruah, X. Yu, S. Vasiljevic, S. Mattick, L.K. Pritchard, B. Krishna, C.N. Scanlan, J.R. Schnell, M.K. Higgins, N. Zitzmann, and M. Crispin Fragments of bacterial endoglycosidase S and immunoglobulin G reveal subdomains of each that contribute to deglycosylation J. Biol. Chem. 289 2014 13876 13889
178. U. von Pawel-Rammingen, and L. Björck IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes Curr. Opin. Microbiol. 6 2003 50 55
179. J. Sjogren, W.B. Struwe, E.F. Cosgrave, P.M. Rudd, M. Stervander, M. Allhorn, A. Hollands, V. Nizet, and M. Collin EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and alpha1-acid glycoprotein Biochem. J. 455 2013 107 118
180. Y. Kanda, T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, R. Kuni-Kamochi, R. Nakano, K. Yano, S. Kakita, K. Shitara, and M. Satoh Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types Glycobiology 17 2007 104 118
181. Q. Zhou, S. Shankara, A. Roy, H. Qiu, S. Estes, A. McVie-Wylie, K. Culm-Merdek, A. Park, C. Pan, and T. Edmunds Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function Biotechnol. Bioeng. 99 2008 652 665
182. M. Crispin, T.A. Bowden, C.H. Coles, K. Harlos, A.R. Aricescu, D.J. Harvey, D.I. Stuart, and E.Y. Jones Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions J. Mol. Biol. 387 2009 1061 1066
183. R.J. Harris Heterogeneity of recombinant antibodies: linking structure to function Dev. Biol. 122 2005 117 127
184. A.M. Goetze, Y.D. Liu, Z. Zhang, B. Shah, E. Lee, P.V. Bondarenko, and G.C. Flynn High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans Glycobiology 21 2011 949 959
185. S.L. Sazinsky, R.G. Ott, N.W. Silver, B. Tidor, J.V. Ravetch, and K.D. Wittrup Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors Proc. Natl. Acad. Sci. 105 2008 20167 20172
186. E.W. Gelfand Differences between IGIV products: impact on clinical outcome Int. Immunopharmacol. 6 2006 592 599
187. H.M. Gürcan, and A.R. Ahmed Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders Ann. Pharmacother. 41 2007 812 823
188. F. Nimmerjahn, and J.V. Ravetch Anti-inflammatory actions of intravenous immunoglobulin Annu. Rev. Immunol. 26 2008 513 533
189. A. Durandy, S.V. Kaveri, T.W. Kuijpers, M. Basta, S. Miescher, J.V. Ravetch, and R. Rieben Intravenous immunoglobulins - understanding properties and mechanisms Clin. Exp. Immunol. 158 2009 2 13
190. M. Ballow The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders J. Allergy Clin. Immunol. 127 2011 315 323
191. I. Schwab, and F. Nimmerjahn Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13 2013 176 189
192. F. Petta, C. De Luca, M. Triggiani, and V. Casolaro Fragments of truth: T-cell targets of polyclonal immunoglobulins in autoimmune diseases Curr. Opin. Pharmacol. 17 2014 1 11
193. F. Rossi, and M.D. Kazatchkine Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig J. Immunol. 143 1989 4104 4109
194. I. Viard, P. Wehrli, R. Bullani, P. Schneider, N. Holler, D. Salomon, T. Hunziker, J.-H. Saurat, J. Tschopp, and L.E. French Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin Science 282 1998 490 493
195. F. Altznauer, S. von Gunten, P. Späth, and H.-U. Simon Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations J. Allergy Clin. Immunol. 112 2003 1185 1190
196. M. Basta, F. Van Goor, S. Luccioli, E.M. Billings, A.O. Vortmeyer, L. Baranyi, J. Szebeni, C.R. Alving, M.C. Carroll, I. Berkower, S.S. Stojilkovic, and D.D. Metcalfe F(ab)[prime]2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins Nat. Med. 9 2003 431 438
197. L. Le Pottier, T.A.L. Sapir, B. Bendaoud, P. Youinou, Y. Shoenfeld, and J.-O. Pers Intravenous immunoglobulin and cytokines Ann. N. Y. Acad. Sci. 1110 2007 426 432
198. M. Debré, C. Griscelli, M.C. Bonnet, E. Carosella, N. Philippe, P. Reinert, E. Vilmer, C. Kaplan, W.H. Fridman, and J.L. Teillaud Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura Lancet 342 1993 945 949
199. B.M. Fiebiger, J. Maamary, A. Pincetic, and J.V. Ravetch Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs Proc. Natl. Acad. Sci. 112 2015 E2385 E2394
200. M. Niknami, M.-X. Wang, T. Nguyen, and J.D. Pollard Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis) J. Peripher. Nerv. Syst. 18 2013 141 152
201. A. Jain, H. Olsen, R. Vyzasatya, E. Burch, Y. Sakoda, E. Merigeon, L. Cai, C. Lu, M. Tan, K. Tamada, D. Schulze, D. Block, and S. Strome Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice Arthritis Res. Ther. 14 2012 R192
202. M. Thiruppathi, J.R. Sheng, L. Li, B.S. Prabhakar, and M.N. Meriggioli Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis J. Autoimmun. 52 2014 64 73
203. S.B. Clarkson, J.B. Bussel, R.P. Kimberly, J.E. Valinsky, R.L. Nachman, and J.C. Unkeless Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody N. Engl. J. Med. 314 1986 1236 1239
204. V. Siragam, A.R. Crow, D. Brinc, S. Song, J. Freedman, and A.H. Lazarus Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells Nat. Med. 12 2006 688 692
205. K.-H. Park-Min, N.V. Serbina, W. Yang, X. Ma, G. Krystal, B.G. Neel, S.L. Nutt, X. Hu, and L.B. Ivashkiv FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin Immunity 26 2007 67 78
206. A. Samuelsson, T.L. Towers, and J.V. Ravetch Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 2001 484 486
207. K.M. Dhodapkar, D. Banerjee, J. Connolly, A. Kukreja, E. Matayeva, M.C. Veri, J.V. Ravetch, R.M. Steinman, and M.V. Dhodapkar Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program J. Exp. Med. 204 2007 1359 1369
208. T.L. McGaha, B. Sorrentino, and J.V. Ravetch Restoration of tolerance in lupus by targeted inhibitory receptor expression Science 307 2005 590 593
209. F. Nimmerjahn, and J.V. Ravetch Divergent immunoglobulin G subclass activity through selective Fc receptor binding Science 310 2005 1510 1512
210. K.A. Nikolova, A.I. Tchorbanov, I.K. Djoumerska-Alexieva, M. Nikolova, and T.L. Vassilev Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc[gamma]IIB receptor on B cells Immunol. Cell Biol. 87 2009 529 533
211. R.J. Hansen, and J.P. Balthasar Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor Thromb. Haemost. 88 2002 898 899
212. N. Li, M. Zhao, J. Hilario-Vargas, P. Prisayanh, S. Warren, L.A. Diaz, D.C. Roopenian, and Z. Liu Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases J. Clin. Invest. 115 2005 3440 3450
213. J.-F. Séïté, D. Cornec, Y. Renaudineau, P. Youinou, R.A. Mageed, and S. Hillion IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes Blood 116 2010 1698 1704
214. R.M. Anthony, F. Wermeling, M.C.I. Karlsson, and J.V. Ravetch Identification of a receptor required for the anti-inflammatory activity of IVIG Proc. Natl. Acad. Sci. 105 2008 19571 19578
215. I. Schwab, M. Biburger, G. Krönke, G. Schett, and F. Nimmerjahn IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1 Eur. J. Immunol. 42 2012 826 830
216. A.H. Massoud, M. Yona, D. Xue, F. Chouiali, H. Alturaihi, A. Ablona, W. Mourad, C.A. Piccirillo, and B.D. Mazer Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells J. Allergy Clin. Immunol. 133 2014 853 863 e855
217. C.L. Haga, G.R.A. Ehrhardt, R.J. Boohaker, R.S. Davis, and M.D. Cooper Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment Proc. Natl. Acad. Sci. 104 2007 9770 9775
218. A. Franco, B. Damdinsuren, T. Ise, J. Dement-Brown, H. Li, S. Nagata, and M. Tolnay Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors J. Immunol. 190 2013 5739 5746
219. Y. Kaneko, F. Nimmerjahn, M.P. Madaio, and J.V. Ravetch Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors J. Exp. Med. 203 2006 789 797
220. I. Schwab, M. Seeling, M. Biburger, S. Aschermann, L. Nitschke, and F. Nimmerjahn B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo Eur. J. Immunol. 42 2012 3302 3309
221. A.R. Crow, S.J. Suppa, X. Chen, P.J. Mott, and A.H. Lazarus The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia Blood 118 2011 6403 6406
222. D. Leontyev, Y. Katsman, and D.R. Branch Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP Blood 119 2012 5261 5264
223. X. Yu, S. Vasiljevic, D.A. Mitchell, M. Crispin, and C.N. Scanlan Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain J. Mol. Biol. 425 2013 1253 1258
224. H. Feinberg, D.A. Mitchell, K. Drickamer, and W.I. Weis Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR Science 294 2001 2163 2166
225. Y. Guo, H. Feinberg, E. Conroy, D.A. Mitchell, R. Alvarez, O. Blixt, M.E. Taylor, W.I. Weis, and K. Drickamer Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR Nat. Struct. Mol. Biol. 11 2004 591 598
226. R. Bazin, R. Lemieux, and T. Tremblay Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody Br. J. Haematol. 135 2006 97 100
227. I. Schwab, A. Lux, and F. Nimmerjahn Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice Cell Rep. 13 2015 610 620
228. R. Malhotra, M.R. Wormald, P.M. Rudd, P.B. Fischer, R.A. Dwek, and R.B. Sim Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein Nat. Med. 1 1995 237 243
229. T.W. Rademacher, P. Williams, and R.A. Dwek Agalactosyl glycoforms of IgG autoantibodies are pathogenic Proc. Natl. Acad. Sci. 91 1994 6123 6127
230. R.B. Parekh, R.A. Dwek, B.J. Sutton, D.L. Fernandes, A. Leung, D. Stanworth, T.W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta, F. Takeuchi, Y. Nagano, T. Miyamoto, and A. Kobata Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG Nature 316 1985 452 457
231. F. van de Geijn, M. Wuhrer, M. Selman, S. Willemsen, Y. de Man, A. Deelder, J. Hazes, and R. Dolhain Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study Arthritis Res. Ther. 11 2009 R193
232. I. Quast, C.W. Keller, M.A. Maurer, J.P. Giddens, B. Tackenberg, L.-X. Wang, C. Münz, F. Nimmerjahn, M.C. Dalakas, and J.D. Lünemann Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity J. Clin. Invest. 125 2015 4160 4170
233. C.M. Oefner, A. Winkler, C. Hess, A.K. Lorenz, V. Holecska, M. Huxdorf, T. Schommartz, D. Petzold, J. Bitterling, A.-L. Schoen, A.D. Stoehr, D. Vu Van, Y. Darcan-Nikolaisen, V. Blanchard, I. Schmudde, Y. Laumonnier, H.A. Ströver, A.N. Hegazy, S. Eiglmeier, C.T. Schoen, M.M.M. Mertes, C. Loddenkemper, M. Löhning, P. König, A. Petersen, E.O. Luger, M. Collin, J. Köhl, A. Hutloff, E. Hamelmann, M. Berger, H. Wardemann, and M. Ehlers Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs J. Allergy Clin. Immunol. 129 2012 1647 1655 e1613
234. C. Hess, A. Winkler, x E, A.K. Lorenz, V. Holecska, V. Blanchard, x E, ronique, S. Eiglmeier, A.-L. Schoen, J. Bitterling, A.D. Stoehr, D. Petzold, T. Schommartz, M.M.M. Mertes, C.T. Schoen, B. Tiburzy, A. Herrmann, xF, J. hl, xF, rg, R.A. Manz, M.P. Madaio, M. Berger, H. Wardemann, and M. Ehlers T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies J. Clin. Invest. 123 2013 3788 3796
235. B.J. Scallon, S.H. Tam, S.G. McCarthy, A.N. Cai, and T.S. Raju Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality Mol. Immunol. 44 2007 1524 1534
236. R.M. Anthony, T. Kobayashi, F. Wermeling, and J.V. Ravetch Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway Nature 475 2011 110 113
237. Y. van Kooyk, and T.B.H. Geijtenbeek DC-SIGN: escape mechanism for pathogens Nat. Rev. Immunol. 3 2003 697 709
238. Juan J. Garcia-Vallejo, and Y. van Kooyk DC-SIGN: the strange case of Dr. Jekyll and Mr. Hyde Immunity 42 2015 983 985
239. D.A. Mitchell, A.J. Fadden, and K. Drickamer A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: subunit organization and binding to multivalent ligands J. Biol. Chem. 276 2001 28939 28945
240. K. Pederson, D.A. Mitchell, and J.H. Prestegard Structural characterization of the DC-SIGN-LewisX complex Biochemistry 53 2014 5700 5709
241. A. Holla, and A. Skerra Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin Protein Eng. Des. Sel. 24 2011 659 669
242. E. van Liempt, C.M.C. Bank, P. Mehta, J.J. GarcI'a-Vallejo, Z.S. Kawar, R. Geyer, R.A. Alvarez, R.D. Cummings, Y.v. Kooyk, and I. van Die Specificity of DC-SIGN for mannose- and fucose-containing glycans FEBS Lett. 580 2006 6123 6131
243. S. Krapp, Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity J. Mol. Biol. 325 2003 979 989
244. A.S. Tjon, R. van Gent, H. Jaadar, P. Martin van Hagen, S. Mancham, L.J. van der Laan, P.A. te Boekhorst, H.J. Metselaar, and J. Kwekkeboom Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production J. Immunol. 192 2014 5625 5634
245. M. Sharma, Y. Schoindre, P. Hegde, C. Saha, M.S. Maddur, E. Stephen-Victor, L. Gilardin, M. Lecerf, P. Bruneval, L. Mouthon, O. Benveniste, S.V. Kaveri, and J. Bayry Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients Sci. Rep. 4 2014 5672
246. J. Bayry, K. Bansal, M.D. Kazatchkine, and S.V. Kaveri DC-SIGN and α2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells Proc. Natl. Acad. Sci. U. S. A. 106 2009 E24
247. M.S. Maddur, J. Vani, P. Hegde, S. Lacroix-Desmazes, S.V. Kaveri, and J. Bayry Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin J. Allergy Clin. Immunol. 127 2011 823 830 e827
248. J. Trinath, P. Hegde, M. Sharma, M.S. Maddur, M. Rabin, J.-M. Vallat, L. Magy, K.N. Balaji, S.V. Kaveri, and J. Bayry Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells Blood 122 2013 1419 1427
249. A.S. Tjon, R. van Gent, T.B. Geijtenbeek, and J. Kwekkeboom Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye Front. Immunol. 6 2015 10.3389/fimmu.2015.00197
250. J.J. Garcia-Vallejo, and Y. van Kooyk The physiological role of DC-SIGN: a tale of mice and men Trends Immunol. 34 2013 482 486
251. A.S. Powlesland, E.M. Ward, S.K. Sadhu, Y. Guo, M.E. Taylor, and K. Drickamer Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins J. Biol. Chem. 281 2006 20440 20449
252. K. Drickamer, and M.E. Taylor Recent insights into structures and functions of C-type lectins in the immune system Curr. Opin. Struct. Biol. 34 2015 26 34
253. A.A. Bashirova, T.B. Geijtenbeek, G.C. van Duijnhoven, S.J. van Vliet, J.B. Eilering, M.P. Martin, L. Wu, T.D. Martin, N. Viebig, P.A. Knolle, V.N. KewalRamani, Y. van Kooyk, and M. Carrington A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection J. Exp. Med. 193 2001 671 678
254. C.E. Angel, C.-J.J. Chen, O.C. Horlacher, S. Winkler, T. John, J. Browning, D. MacGregor, J. Cebon, and P.R. Dunbar Distinctive localization of antigen-presenting cells in human lymph nodes Blood 113 2009 1257 1267
255. A. Granelli-Piperno, A. Pritsker, M. Pack, I. Shimeliovich, J.F. Arrighi, C.G. Park, C. Trumpfheller, V. Piguet, T.M. Moran, and R.M. Steinman Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction J. Immunol. 175 2005 4265 4273
256. L.D. Powell, D. Sgroi, E.R. Sjoberg, I. Stamenkovic, and A. Varki Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition J. Biol. Chem. 268 1993 7019 7027
257. T. Angata, and A. Varki Chemical diversity in the sialic acids and related α-keto acids: an evolutionary perspective Chem. Rev. 102 2002 439 470
258. T. Kawano, S. Koyama, H. Takematsu, Y. Kozutsumi, H. Kawasaki, S. Kawashima, T. Kawasaki, and A. Suzuki Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid J. Biol. Chem. 270 1995 16458 16463
259. A. Irie, S. Koyama, Y. Kozutsumi, T. Kawasaki, and A. Suzuki The molecular basis for the absence of N-glycolylneuraminic acid in humans J. Biol. Chem. 273 1998 15866 15871
260. E.C. Brinkman-Van der Linden, E.R. Sjoberg, L.R. Juneja, P.R. Crocker, N. Varki, and A. Varki Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs J. Biol. Chem. 275 2000 8633 8640
261. E.E. Bates, N. Fournier, E. Garcia, J. Valladeau, I. Durand, J.J. Pin, S.M. Zurawski, S. Patel, J.S. Abrams, S. Lebecque, P. Garrone, and S. Saeland APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif J. Immunol. 163 1999 1973 1983
262. N. Fujikado, S. Saijo, T. Yonezawa, K. Shimamori, A. Ishii, S. Sugai, H. Kotaki, K. Sudo, M. Nose, and Y. Iwakura DCIR deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells Nat. Med. 14 2008 176 180
263. R.T. Lee, T.L. Hsu, S.K. Huang, S.L. Hsieh, C.H. Wong, and Y.C. Lee Survey of immune-related, mannose/fucose-binding C-type lectin receptors reveals widely divergent sugar-binding specificities Glycobiology 21 2011 512 520
264. K. Bloem, I.M. Vuist, A.-J. van der Plas, L.M.J. Knippels, J. Garssen, J.J. García-Vallejo, S.J. van Vliet, and Y. van Kooyk Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain PLoS One 8 2013 e66266
265. R.S. Davis, Y.H. Wang, H. Kubagawa, and M.D. Cooper Identification of a family of Fc receptor homologs with preferential B cell expression Proc. Natl. Acad. Sci. 98 2001 9772 9777
266. I. Miller, G. Hatzivassiliou, G. Cattoretti, C. Mendelsohn, and R. Dalla-Favera IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells Blood 99 2002 2662 2669
267. R.S. Davis Fc receptor-like molecules Annu. Rev. Immunol. 25 2007 525 560
268. T. Ise, H. Maeda, K. Santora, L. Xiang, R.J. Kreitman, I. Pastan, and S. Nagata Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies Clin. Cancer Res. 11 2005 87 96
269. T. Ise, S. Nagata, R.J. Kreitman, W.H. Wilson, A.S. Wayne, M. Stetler-Stevenson, M.R. Bishop, D.A. Scheinberg, L. Rassenti, T.J. Kipps, R.A. Kyle, D.F. Jelinek, and I. Pastan Elevation of soluble CD307 (IRTA2//FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma Leukemia 21 2006 169 174
270. K. Elkins, B. Zheng, M. Go, D. Slaga, C. Du, S.J. Scales, S.F. Yu, J. McBride, R. de Tute, A. Rawstron, A.S. Jack, A. Ebens, and A.G. Polson FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma Mol. Cancer Ther. 11 2012 2222 2232
271. T.J. Wilson, A. Fuchs, and M. Colonna Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG J. Immunol. 188 2012 4741 4745
272. F. Käsermann, D.J. Boerema, M. Rüegsegger, A. Hofmann, S. Wymann, A.W. Zuercher, and S. Miescher Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIg) after lectin fractionation PLoS One 7 2012 e37243
273. S.Q. Nagelkerke, G. Dekkers, I. Kustiawan, F.S. van de Bovenkamp, J. Geissler, R. Plomp, M. Wuhrer, G. Vidarsson, T. Rispens, T.K. van den Berg, and T.W. Kuijpers Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages Blood 124 2014 3709 3718
274. A.C. Issekutz, D. Rowter, S. Miescher, and F. Käsermann Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells Clin. Immunol. 160 2015 123 132
275. D. Leontyev, Y. Katsman, X.-Z. Ma, S. Miescher, F. Käsermann, and D.R. Branch Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin Transfusion 52 2012 1799 1805
276. T. Guhr, J. Bloem, N.I.L. Derksen, M. Wuhrer, A.H.L. Koenderman, R.C. Aalberse, and T. Rispens Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia PLoS One 6 2011 e21246
277. S. Othy, S. Topçu, C. Saha, P. Kothapalli, S. Lacroix-Desmazes, F. Käsermann, S. Miescher, J. Bayry, and S.V. Kaveri Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin Eur. J. Immunol. 44 2014 2059 2063
278. I.K. Campbell, S. Miescher, D.R. Branch, P.J. Mott, A.H. Lazarus, D. Han, E. Maraskovsky, A.W. Zuercher, A. Neschadim, D. Leontyev, B.S. McKenzie, and F. Käsermann Therapeutic effect of IVIg on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils J. Immunol. 192 2014 5031 5038
279. C. Ramakrishna, A.N.S. Newo, Y.-W. Shen, and E. Cantin Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis PLoS Pathog. 7 2011 e1002071
280. J. Bayry, M.D. Kazatchkine, and S.V. Kaveri Shortage of human intravenous immunoglobulin - reasons and possible solutions Nat. Rev. Neurol. 3 2007 120 121
281. E.O. Saphire, R.L. Stanfield, M.D. Crispin, G. Morris, M.B. Zwick, R.A. Pantophlet, P.W. Parren, P.M. Rudd, R.A. Dwek, D.R. Burton, and I.A. Wilson Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design Adv. Exp. Med. Biol. 535 2003 55 66
282. E.O. Saphire, P.W. Parren, R. Pantophlet, M.B. Zwick, G.M. Morris, P.M. Rudd, R.A. Dwek, R.L. Stanfield, D.R. Burton, and I.A. Wilson Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design Science 293 2001 1155 1159
283. D.J. Harvey, A.H. Merry, L. Royle, M.P. Campbell, R.A. Dwek, and P.M. Rudd Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds Proteomics 9 2009 3796 3801
284. J.F.G. Vliegenthart, L. Dorland, and H. van Halbeek High-resolution 1H nuclear magnetic resonance spectroscopy as a tool in the structural analysis of carbohydrates related to glycoproteins. Adv. Carbohydr. Chem. Biochem. 41 1983 209 374
285. R.A. Dwek, A.C. Lellouch, and M.R. Wormald Glycobiology: 'the function of sugar in the IgG molecule' J. Anat. 187 Pt 2 1995 279 292